TB infection in adults with diabetes mellitus in Uganda
METHODS: Eligible consenting adults were recruited for this cross-sectional study at an outpatient diabetes clinic using systematic random sampling. Data were collected using a pre-tested case report form. TBI was defined as a positive QuantiFERON® Gold Plus test (QFT-Plus) result. Factors associated with TBI were determined using modified Poisson regression analysis in Stata BE v.16.0.
RESULTS: Among the 185 study participants, over two thirds were female and 87.6% (n = 162) were receiving metformin therapy. More than two thirds (143/185) had poor glycaemic control. TBI prevalence was 57.8% (107/185). Concurrent calcium channel blocker (adjusted prevalence ratio [aPR] 1.33, 95% CI 1.05–1.69) and pregabalin therapies (aPR 1.45, 95% CI 1.15–1.84) were independently associated with TBI.
CONCLUSIONS: DM individuals on calcium channel blocker and pregabalin therapies should be routinely screened for TBI. Further studies should investigate the mechanisms of commonly used drugs for TBI in patients with DM in Uganda.
Document Type: Research Article
Affiliations: 1: School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda, Directorate of Programs, The AIDS Support Organisation (U) Ltd, Kampala, Uganda 2: Tuberculosis and Comorbidities Research Group, Makerere University, Kampala, Uganda 3: Tuberculosis and Comorbidities Research Group, Makerere University, Kampala, Uganda, Department of Molecular Biology and Immunology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda 4: School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda 5: Department of Medicine, Lubaga Hospital, Kampala, Uganda 6: School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda, Tuberculosis and Comorbidities Research Group, Makerere University, Kampala, Uganda, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda
Publication date: April 1, 2023
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content